Fantin B, Pangon B, Potel G, Caron F, Vallée E, Vallois J M, Mohler J, Buré A, Philippon A, Carbon C
Institut National de la Santé et de la Recherche Médicale U:13, Hôpital Claude Bernard, Paris, France.
Antimicrob Agents Chemother. 1990 Apr;34(4):581-6. doi: 10.1128/AAC.34.4.581.
We studied the efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ceftriaxone in vitro and in experimental endocarditis due to an Escherichia coli strain producing an extended-spectrum beta-lactamase most similar to SHV-2, a new mechanism of resistance to broad-spectrum cephalosporins among members of the family Enterobacteriaceae. In vitro, ceftriaxone demonstrated an important inoculum effect (MICs were 2 and 256 micrograms/ml with 5 X 10(5) and 5 X 10(7) CFU of inoculum per ml, respectively). Sulbactam inhibited the beta-lactamase degradation of ceftriaxone and enhanced the killing by ceftriaxone with both inocula tested. In vivo, sulbactam (100 mg/kg every 8 h) or ceftriaxone (15 or 30 mg/kg every 24 h) alone were ineffective after a 4-day therapy. The addition of sulbactam to ceftriaxone (15 mg/kg) or to the ceftriaxone (15 mg/kg)-netilmicin (6 mg/kg every 24 h) combination produced a reduction of 2 log10 CFU/g of vegetation greater than that produced by therapy without sulbactam. The sulbactam-ceftriaxone (30 mg/kg) combination produced a reduction of almost 5 log10 CFU/g of vegetation greater than that produced by single-drug therapy (P less than 0.01), sterilized five of eight vegetations (versus none of seven for ceftriaxone [30 mg/kg] alone; P less than 0.05), and was as effective as the ceftriaxone (15 mg/kg)-sulbactam-netilmicin combination. We concluded that (i) SHV-2 production was responsible for ceftriaxone failure in vivo, probably because of the high inoculum present in vegetations; (ii) sulbactam used in a regimen which provided levels in serum constantly above 4 micrograms/ml and a vegetation/serum peak ratio of approximately 1:3 enhanced the activity of a broad-spectrum cephalosporin in a severe experimental infection; and (iii) the highest dose of ceftriaxone in combination with sulbactam was as effective as the lowest dose of ceftriaxone plus sulbactam plus an aminoglycoside.
我们研究了β-内酰胺酶抑制剂舒巴坦与头孢曲松联合应用在体外以及针对一株产生超广谱β-内酰胺酶(与SHV-2极为相似,这是肠杆菌科成员中对广谱头孢菌素产生耐药性的一种新机制)的大肠杆菌所致实验性心内膜炎中的疗效。在体外,头孢曲松表现出显著的接种量效应(接种量分别为每毫升5×10⁵和5×10⁷CFU时,MIC分别为2和256微克/毫升)。舒巴坦抑制了头孢曲松的β-内酰胺酶降解,并增强了头孢曲松对两种测试接种量的杀菌作用。在体内,单独使用舒巴坦(每8小时100毫克/千克)或头孢曲松(每24小时15或30毫克/千克)进行4天治疗后均无效。将舒巴坦添加到头孢曲松(15毫克/千克)或头孢曲松(15毫克/千克)-奈替米星(每24小时6毫克/千克)联合用药方案中,与不使用舒巴坦的治疗相比,使赘生物中的细菌数量减少了2个对数10CFU/克以上。舒巴坦-头孢曲松(30毫克/千克)联合用药方案使赘生物中的细菌数量减少了近5个对数10CFU/克,比单药治疗减少的量更多(P<0.01),使8个赘生物中的5个达到无菌状态(而头孢曲松[30毫克/千克]单药治疗7个赘生物均未达到无菌状态;P<0.05),并且与头孢曲松(15毫克/千克)-舒巴坦-奈替米星联合用药方案效果相当。我们得出结论:(i)SHV-2的产生是体内头孢曲松治疗失败的原因,可能是由于赘生物中存在高接种量;(ii)在一种能使血清水平持续高于4微克/毫升且赘生物/血清峰浓度比约为1:3的给药方案中使用舒巴坦,可增强广谱头孢菌素在严重实验性感染中的活性;(iii)头孢曲松与舒巴坦联合使用的最高剂量与头孢曲松最低剂量加舒巴坦加一种氨基糖苷类药物的效果相当。